Sujet(s)
Avortement provoqué , Structures de l'embryon , Soins aux patients , Santé reproductive , Techniques de reproduction assistée , Santé des femmes , Humains , Alabama , Activisme politique , États-Unis , Interruption légale de grossesse/législation et jurisprudence , Avortement provoqué/législation et jurisprudence , Soins aux patients/normes , Santé des femmes/législation et jurisprudence , Santé des femmes/normes , Santé reproductive/législation et jurisprudence , Santé reproductive/normes , Techniques de reproduction assistée/législation et jurisprudenceRÉSUMÉ
We are living in a golden age of medicine in which the availability of prenatal diagnosis, fetal therapy, and gene therapy/editing make it theoretically possible to repair almost any defect in the genetic code. Furthermore, the ability to diagnose genetic disorders before birth and the presence of established surgical techniques enable these therapies to be delivered safely to the fetus. Prenatal therapies are generally used in the second or early third trimester for severe, life-threatening disorders for which there is a clear rationale for intervening before birth. While there has been promising work for prenatal gene therapy in preclinical models, the path to a clinical prenatal gene therapy approach is complex. We recently held a conference with the University of California, San Francisco-Stanford Center of Excellence in Regulatory Science and Innovation, researchers, patient advocates, regulatory (members of the Food and Drug Administration), and other stakeholders to review the scientific background and rationale for prenatal somatic cell gene therapy for severe monogenic diseases and initiate a dialogue toward a safe regulatory path for phase 1 clinical trials. This review represents a summary of the considerations and discussions from these conversations.
Sujet(s)
Foetus , Thérapie génétique , Femelle , Humains , Parturition , Grossesse , États-Unis , Food and Drug Administration (USA)RÉSUMÉ
The ISSCR has developed the Informed Consent Standards for Human Fetal Tissue Donation and Research to promote uniformity and transparency in tissue donation and collection. This standard is designed to assist those working with and overseeing the regulation of such tissue and reassure the wider community and public.
Sujet(s)
Consentement libre et éclairé , Acquisition d'organes et de tissus , Foetus , HumainsSujet(s)
Avortement provoqué/législation et jurisprudence , Droits civiques/législation et jurisprudence , Droits procréatifs/législation et jurisprudence , Décisions de la Cour Suprême (USA) , Interruption légale de grossesse/législation et jurisprudence , Femelle , Humains , Grossesse , Sexisme/législation et jurisprudence , Texas , États-UnisRÉSUMÉ
The International Society for Stem Cell Research has updated its Guidelines for Stem Cell Research and Clinical Translation in order to address advances in stem cell science and other relevant fields, together with the associated ethical, social, and policy issues that have arisen since the last update in 2016. While growing to encompass the evolving science, clinical applications of stem cells, and the increasingly complex implications of stem cell research for society, the basic principles underlying the Guidelines remain unchanged, and they will continue to serve as the standard for the field and as a resource for scientists, regulators, funders, physicians, and members of the public, including patients. A summary of the key updates and issues is presented here.
Sujet(s)
Questions bioéthiques/normes , Politique (principe) , Guides de bonnes pratiques cliniques comme sujet , Sociétés savantes/normes , Recherche sur les cellules souches/éthique , Cellules souches , Humains , Sociétés savantes/éthiqueRÉSUMÉ
Engineering biology is being applied toward solving or mitigating some of the greatest challenges facing society. As with many other rapidly advancing technologies, the development of these powerful tools must be considered in the context of ethical uses for personal, societal, and/or environmental advancement. Researchers have a responsibility to consider the diverse outcomes that may result from the knowledge and innovation they contribute to the field. Together, we developed a Statement of Ethics in Engineering Biology Research to guide researchers as they incorporate the consideration of long-term ethical implications of their work into every phase of the research lifecycle. Herein, we present and contextualize this Statement of Ethics and its six guiding principles. Our goal is to facilitate ongoing reflection and collaboration among technical researchers, social scientists, policy makers, and other stakeholders to support best outcomes in engineering biology innovation and development.
Sujet(s)
Bioingénierie/éthique , Recherche biomédicale/éthique , Inventions/éthique , Personnel administratif/éthique , Communication , Santé environnementale , Humains , Personnel de laboratoire d'analyses médicales/éthique , Santé publique , Plan de recherche , Personnel de recherche/éthique , Responsabilité socialeSujet(s)
Accessibilité des services de santé/législation et jurisprudence , Couverture d'assurance/législation et jurisprudence , Patient Protection and Affordable Care Act (USA)/législation et jurisprudence , Droits procréatifs/législation et jurisprudence , Décisions de la Cour Suprême (USA) , Femelle , Humains , Mâle , Personnes sans assurance médicale/législation et jurisprudence , États-UnisRÉSUMÉ
Germline genome editing has garnered dire predictions about its societal effects, but experience with other reproductive technologies should caution us about making extravagant claims. Amniocentesis was predicted to result in increased stigmatization of people born with Down syndrome, but in fact people with these conditions have been increasingly integrated into schools and workplaces. Artificial insemination by donor was predicted to result in women choosing to "optimize" their children, but in fact most women eschewed the offerings of the so-called "genius sperm bank," and when choosing among donors, have tended to look for those who most resemble their husbands and partners. IVF was predicted to cause parents to view children as commodities, but no such change has been evidenced. Preimplantation genetic diagnosis was predicted to become widespread and used for an ever-increasing range of conditions, including those unrelated to serious disease or shortened life span, but this has not happened either. Critics of germline genome editing have argued that even if it were safe and effective, it would inevitably be abused by prospective parents who wish to improve upon what is already predicted to be a healthy outcome, and that this practice would become sufficiently widespread among those able to afford it that we would be creating a new genetic caste system. Before developing policy around such predictions, it is important to learn from the past.
Sujet(s)
Édition de gène/éthique , Parents , Amniocentèse/éthique , Marqueurs biologiques , Syndrome de Down/diagnostic , Fécondation in vitro , Édition de gène/législation et jurisprudence , Cellules germinales , Humains , Insémination artificielle , Don d'ovocytes/effets indésirables , Diagnostic préimplantatoire/éthique , Présélection du sexeRÉSUMÉ
Organoids derived from stem cells or tissues in culture can develop into structures that resemble the in vivo anatomy and physiology of intact organs. Human organoid cultures provide the potential to study human development and model disease processes with the same scrutiny and depth of analysis customary for research with nonhuman model organisms. Resembling the complexity of the actual tissue or organ, patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine, generating knowledge and tools for preclinical studies, including drug development and testing. Biologists are drawn to this system as a new "model organism" to study complex disease phenotypes and genetic variability among individuals using patient-derived tissues. The American Society for Cell Biology convened a task force to report on the potential, challenges, and limitations for human organoid research. The task force suggests ways to ease the entry for new researchers into the field and how to facilitate broader use of this new model organism within the research community. This includes guidelines for reproducibility, culturing, sharing of patient materials, patient consent, training, and communication with the public.